Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation

A A Case Rep. 2015 Jun 1;4(11):151-4. doi: 10.1213/XAA.0000000000000143.

Abstract

The management of life-threatening bleeding associated with rivaroxaban remains a challenge for physicians due to the lack of evidence about clinically effective options for anticoagulation reversal. We report a favorable outcome in a patient receiving rivaroxaban prophylaxis, who developed a spontaneous subdural hematoma treated by a surgical evacuation and administration of 4-factor prothrombin complex concentrate. Classical coagulation variables were associated with impaired thrombin generation. Reversal with prothrombin complex concentrates improved all thrombin generation measures. Thrombin generation tests may be suitable for assessing the clinical utility of reversal drugs on rivaroxaban-induced coagulopathy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage
  • Blood Coagulation / drug effects
  • Blood Coagulation Factors / therapeutic use*
  • Blood Coagulation Tests
  • Cerebral Hemorrhage / chemically induced
  • Cerebral Hemorrhage / drug therapy*
  • Factor Xa Inhibitors / adverse effects*
  • Hematoma, Subdural / chemically induced
  • Hematoma, Subdural / therapy
  • Humans
  • Male
  • Rivaroxaban / adverse effects*
  • Thrombin / biosynthesis

Substances

  • Anticoagulants
  • Blood Coagulation Factors
  • Factor Xa Inhibitors
  • prothrombin complex concentrates
  • Rivaroxaban
  • Thrombin